Importantly, ongoing efforts to develop therapeutic strategies preventing TDP-43-associated splicing defects [10] may benefit patients with a range of neurological conditions including ALS, FTD and Alzheimer’s disease. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.